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BACKGROUND
Levodopa is the main treatment for symptoms of Parkinson’s disease. Determining wheth-
er levodopa also has a disease-modifying effect could provide guidance as to when in the 
course of the disease the treatment with this drug should be initiated.
METHODS
In a multicenter, double-blind, placebo-controlled, delayed-start trial, we randomly assigned 
patients with early Parkinson’s disease to receive levodopa (100 mg three times per day) in 
combination with carbidopa (25 mg three times per day) for 80 weeks (early-start group) 
or placebo for 40 weeks followed by levodopa in combination with carbidopa for 40 weeks 
(delayed-start group). The primary outcome was the between-group difference in the mean 
change from baseline to week 80 in the total score on the Unified Parkinson’s Disease Rat-
ing Scale (UPDRS; scores range from 0 to 176, with higher scores signifying more severe 
disease). Secondary analyses included the progression of symptoms, as measured by the 
UPDRS score, between weeks 4 and 40 and the noninferiority of early initiation of treatment 
to delayed initiation between weeks 44 and 80, with a noninferiority margin of 0.055 points 
per week.
RESULTS
A total of 445 patients were randomly assigned: 222 to the early-start group and 223 to the 
delayed-start group. The mean (±SD) UPDRS score at baseline was 28.1±11.4 points in the 
early-start group and 29.3±12.1 points in the delayed-start group. The change in UPDRS 
score from baseline to week 80 was −1.0±13.1 points and −2.0±13.0 points, respectively 
(difference, 1.0 point; 95% confidence interval [CI], −1.5 to 3.5; P = 0.44); this finding of no 
significant between-group difference at week 80 implies that levodopa had no disease-
modifying effect. Between weeks 4 and 40, the rate of progression of symptoms, as mea-
sured in UPDRS points per week, was 0.04±0.23 in the early-start group and 0.06±0.34 in 
the delayed-start group (difference, −0.02; 95% CI, −0.07 to 0.03). The corresponding rates 
between weeks 44 and 80 were 0.10±0.25 and 0.03±0.28 (difference, 0.07; two-sided 90% 
CI, 0.03 to 0.10); the difference in the rate of progression between weeks 44 and 80 did not 
meet the criterion for noninferiority of early receipt of levodopa to delayed receipt. The rates 
of dyskinesia and levodopa-related fluctuations in motor response did not differ signifi-
cantly between the two groups.
CONCLUSIONS
Among patients with early Parkinson’s disease who were evaluated over the course of 
80 weeks, treatment with levodopa in combination with carbidopa had no disease-modify-
ing effect. (Funded by the Netherlands Organization for Health Research and Development 
and others; LEAP Current Controlled Trials number, ISRCTN30518857.)
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The main treatment for Parkinson’s disease is the dopamine precursor levo-dopa. Physicians may delay initiation of 
levodopa for various reasons, including concern 
about the induction of dyskinesias.1,2 However, 
almost all patients ultimately receive levodopa to 
control motor symptoms.3 In the Earlier versus 
Later Levodopa Therapy in Parkinson Disease 
(ELLDOPA) trial, the results of which were re-
ported previously in the Journal,4 patients with 
early Parkinson’s disease received levodopa or 
placebo, and after 40 weeks the trial regimen 
was stopped. Two weeks after cessation of the 
regimen, the condition of the patients who had 
received levodopa had not deteriorated to the 
same degree as that of the patients who had 
received placebo, which suggested either that 
levodopa had slowed the progression of Parkin-
son’s disease or that the drug had had a pro-
longed effect on symptoms that was interpreted 
as ameliorating the underlying disease. In con-
trast to these clinical results, neuroimaging data 
from that trial suggested either that levodopa had 
the detrimental effect of accelerating the loss of 
dopamine nerve terminals or that it modified 
the striatal dopamine transporter.4 Therefore, 
whether levodopa has an effect on the progres-
sion of Parkinson’s disease beyond its immedi-
ate benefit with respect to symptoms remains 
unknown.
One method of separating a possible disease-
modifying effect of levodopa from an effect on 
symptoms is by conducting a delayed-start trial 
in two phases. During phase 1, patients receive 
either the active drug or placebo. A difference 
between the groups at the end of this phase may 
be the result of an effect on symptoms, a dis-
ease-modifying effect, or both. During phase 2, 
both groups receive the active drug, and persis-
tent differences between the groups at the end 
of this phase are presumed to be explained by a 
disease-modifying effect because the effects of 
the drug on symptoms at that time are the same 
in both groups.5 Here, we report the results of 
the delayed-start trial Levodopa in Early Parkin-
son’s Disease (LEAP), which evaluated whether 
levodopa has a disease-modifying effect on pa-
tients with early Parkinson’s disease who had 
insufficient disability to warrant treatment with 
antiparkinson medication.
Me thods
Trial Oversight
This was a multicenter, randomized, double-blind, 
placebo-controlled, delayed-start trial. Patients 
were recruited from 50 community hospitals and 
7 academic hospitals in the Netherlands. The 
trial design has been published previously.6 The 
protocol, which was approved by the ethics com-
mittee at the Amsterdam University Medical Cen-
ters in the Netherlands, is available with the full 
text of this article at NEJM.org. The trial was 
conducted in accordance with the principles of 
the Declaration of Helsinki. Trial monitoring and 
data management were performed in accordance 
with the International Conference on Harmoni-
sation Good Clinical Practice guidelines. Combi-
nation tablets of levodopa (100 mg) and carbi-
dopa (25 mg) and matching placebo tablets were 
manufactured by and delivered to the participat-
ing patients by ACE Pharmaceuticals (Zeewolde, 
the Netherlands), which did not have any other 
role in the trial, including in the design or con-
duct of the trial, the analysis of the data, or the 
preparation of the manuscript. The authors vouch 
for the accuracy and completeness of the data 
and analyses and for the fidelity of the trial to 
the protocol. All the patients provided written 
informed consent. There was no industry involve-
ment in the trial.
Patients
Patients were eligible for enrollment if they had 
received a diagnosis of Parkinson’s disease with-
in the previous 2 years from an experienced neu-
rologist who based the diagnosis on standard 
clinical criteria,7 if they had insufficient disability 
to warrant treatment with antiparkinson medi-
cation, if they were 30 years of age or older, and if 
they had a life expectancy of more than 2 years. 
Patients who had been treated previously with 
antiparkinson medication (e.g., levodopa, dopa-
mine agonists, monoamine oxidase B inhibitor, 
catechol O-methyltransferase inhibitor, or aman-
tadine) were excluded. Patients were also excluded 
if their most prominent symptom was tremor, 
such as a severe resting tremor that was present 
almost continuously or resulted in disability; if 
they had dementia; and if they had features that 
indicated atypical or secondary parkinsonism.
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Trial Procedures
After a baseline assessment, patients were ran-
domly assigned, in a 1:1 ratio by a central Web-
based computer program, to receive oral levo-
dopa (100 mg three times per day) in combination 
with oral carbidopa (25 mg three times per day) 
for 80 weeks (early-start group) or to receive 
placebo three times per day for 40 weeks fol-
lowed by oral levodopa (100 mg three times per 
day) in combination with oral carbidopa (25 mg 
three times per day) for 40 weeks (delayed-start 
group). Randomization was stratified according 
to type of hospital (academic vs. community hos-
pital), age (<65 vs. ≥65 years), and duration of 
symptoms (<0.5 vs. ≥0.5 years) and was per-
formed with the use of variable permuted blocks, 
with block sizes ranging from two to eight pa-
tients. During phase 1, the first 40 weeks of the 
trial, patients received levodopa or placebo. Dur-
ing phase 2, the second 40 weeks, patients in 
both trial groups received levodopa. If a disabil-
ity involving activities of daily living developed 
during the first 40 weeks and the clinician de-
termined that treatment for the disability should 
be administered, the patient was switched from 
the blinded treatment of phase 1 (levodopa in the 
early-start group and placebo in the delayed-start 
group) to open-label levodopa for the remainder 
of phase 1. If such a scenario occurred in a pa-
tient in the early-start group, the patient contin-
ued to receive the same dose of levodopa. Mask-
ing of the initial treatment assignment was 
preserved for both the patient and the investiga-
tor. Assessments were performed by trained re-
search nurses at baseline and at weeks 4, 22, 40, 
44, 56, 68, and 80.
Outcomes
The primary outcome was the difference between 
the early-start group and the delayed-start group 
in the mean change from baseline to week 80 in 
the total score on the Unified Parkinson’s Dis-
ease Rating Scale (UPDRS). The UPDRS includes 
subscales of mental function, activities of daily 
living, and motor function; total scores on the 
scale range from 0 to 176, with higher scores 
indicating more severe disease.8 The main sec-
ondary outcomes were the progression of symp-
toms between weeks 4 and 40 and between 
weeks 44 and 80, as measured by the score on 
the UPDRS. Additional secondary outcomes at 
80 weeks were disability as assessed by the Aca-
demic Medical Center Linear Disability Score 
(ALDS; scores range from 0 to 100, with lower 
scores indicating greater disability),9 cognitive 
impairment as assessed by the Mini–Mental 
State Examination (MMSE; scores range from 
0 to 30, with lower scores indicating greater 
cognitive impairment),10 depression as assessed 
by the Beck Depression Inventory II (BDI-II; 
scores range from 0 to 63, with higher scores 
indicating more severe depressive symptoms),11 
and disease-related quality of life as assessed by 
the Parkinson’s Disease Questionnaire-39 (PDQ-39; 
scores range from 0 to 100, with higher scores 
indicating a lower disease-related quality of life).12 
Outcomes at other time points are described in 
the protocol. In addition, we assessed the number 
of patients who received additional antiparkin-
son medication, the number of patients who had 
treatment complications including dyskinesia and 
levodopa-related fluctuations in motor response, 
and the type, incidence, and duration of adverse 
events.
Statistical Analysis
On the basis of the results of the ELLDOPA trial, 
we anticipated a mean (±SD) difference between 
the groups of 4±13 points on the UPDRS in the 
primary outcome in favor of the early-start 
group.4 This magnitude of difference has been 
considered to be clinically relevant.13 We calcu-
lated that enrollment of 167 patients in each 
group would provide the trial with 80% power to 
detect a difference in the UPDRS mean score of 
4 points, using Student’s t-test at a two-sided 
alpha level of 0.05. Assuming a dropout rate of 
25%,4,14,15 we planned to include 223 patients in 
each trial group.
Data were analyzed according to the intention-
to-treat principle. Patients who proceeded to re-
ceive the phase 2 treatment before week 40 as a 
result of the need for control of symptoms were 
included in the group to which they had been 
randomly assigned.
The main analysis was a comparison of the 
primary outcome between the two trial groups at 
week 80. First, the difference between the groups 
in the mean change from baseline to week 80 in 
the total UPDRS score was analyzed with the use 
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of Student’s t-test. Second, the UPDRS scores 
at 80 weeks were assessed with the use of an 
analysis of covariance model, taking into ac-
count baseline UPDRS scores. We used linear 
mixed-model analysis, model-based multiple im-
putation, and per-protocol analyses to evaluate 
the robustness of the results and to address the 
issue of missing data. Patients were excluded 
from the per-protocol analyses if they had re-
ceived additional antiparkinson medication (e.g., 
patients who received phase 2 treatment during 
the first 40 weeks of the trial), if they had not 
received the correct treatment or the correct dose 
of the treatment, or if they did not have assess-
ments at baseline, week 4, week 40, week 44, or 
week 80.
The main secondary analysis was a compari-
son of the progression of symptoms between 
weeks 4 and 40 (phase 1) and between weeks 44 
and 80 (phase 2); a random-effects model was 
used to account for the repeated measures within 
patients. Progression of symptoms was gauged 
on the basis of the weekly change in the mean 
UPDRS score. We used the measurements at 
weeks 4, 22, and 40 and the measurements at 
weeks 44, 56, 68, and 80 to estimate the differ-
ence in the rate of progression between the two 
trial groups. If progression was found to occur 
more rapidly in the delayed-start group than in 
the early-start group during phase 1, but non-
inferiority of the early-start group to the delayed-
start group with respect to the rate of progres-
sion was not shown during phase 2, this finding 
was to be interpreted as showing the effect of 
levodopa only on symptoms, with no disease-
modifying effect. We used noninferiority tests 
only for analyses of rates of progression during 
phase 2. A noninferiority margin of 0.055 points 
on the UPDRS, which represents 2 UPDRS points 
during a period of 36 weeks, was prespecified. 
Noninferiority for phase 2 was assessed with the 
use of two-sided 90% confidence intervals (95% 
one-sided confidence intervals). The rate of pro-
gression between weeks 4 and 40 and between 
weeks 44 and 80 was also analyzed with the use 
of a per-protocol approach with data from pa-
tients who had had UPDRS scores in the highest 
quartile of scores at baseline and who also were 
adherent to the trial protocol. There was no plan 
for correction for multiple comparisons of sec-
ondary outcomes; these results are presented as 
point estimates with unadjusted 95% confidence 
intervals, without P values.
We also analyzed the between-group differ-
ence in the mean score on the UPDRS at 80 
weeks in prespecified subgroups defined accord-
ing to type of hospital, age, and duration of dis-
ease. For comparisons of the other outcomes 
(ALDS, MMSE, BDI-II, and PDQ-39), we used the 
appropriate parametric and nonparametric sta-
tistics; details are provided in the Supplementary 
Appendix, available at NEJM.org. Two-sided P val-
ues of less than 0.05 were considered to indicate 
statistical significance. Analyses were performed 
with the use of SPSS software, version 24.
R esult s
Patients
From August 2011 through May 2016, a total of 
446 patients were enrolled. One patient with-
drew from the trial before the baseline assess-
ment. Thus, 445 patients underwent randomiza-
tion: 222 patients were randomly assigned to the 
early-start group and 223 to the delayed-start 
group (Fig. 1). A total of 207 patients in the 
early-start group and 210 patients in the delayed-
start group completed the 80-week trial. Because 
of a need for symptomatic relief, 87 patients in 
the delayed-start group proceeded to receive the 
phase 2 trial medication (levodopa) before week 
40, and 24 patients in the early-start group pro-
ceeded to open-label treatment with the same 
dose of levodopa. The demographic and clinical 
characteristics of the two groups were similar at 
baseline, with a mean (±SD) UPDRS score of 
28.1±11.4 in the early-start group and 29.3±12.1 
in the delayed-start group (Table 1). Before evalu-
ation for eligibility for enrollment, 98 patients 
(22%) had undergone imaging of the dopamine 
transporter, which confirmed degeneration of 
substantia nigra neurons.
Outcomes
The difference between the groups in the mean 
change from baseline to week 80 in the total 
score on the UPDRS, the primary outcome, was 
not significant. The mean change was −1.0±13.1 
points in the early-start group and −2.0±13.0 
points in the delayed-start group, with a decrease 
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in points signifying improvement; the between-
group difference was 1.0 point (95% confidence 
interval [CI], −1.5 to 3.5; P = 0.44). An analysis 
adjusted for baseline scores on the UPDRS also 
showed no significant difference between the 
groups at 80 weeks (difference, 0.6 points; 95% 
Figure 1. Enrollment and Randomization.
For one patient in the delayed-start group who completed the trial, the Unified Parkinson’s Disease Rating Scale 
(UPDRS) score was not available at 80 weeks.
445 Underwent randomization
446 Were enrolled in the trial
1 Withdrew from the trial
before baseline measure-
ments and randomization
766 Patients were assessed for eligibility
320 Were excluded
53 Did not meet inclusion criteria
198 Declined to participate
69 Had other reasons
222 Were assigned to early-start levodopa
and entered phase 1
223 Were assigned to delayed-start
levodopa and entered phase 1
11 Were withdrawn early
1 Died
8 Withdrew consent
1 Had an adverse event
1 Did not have Parkinson’s
disease
24 Had early transfer to phase 2
5 Transferred before 22 wk
19 Transferred before 40 wk
8 Were withdrawn early
2 Died
5 Withdrew consent
1 Did not have Parkinson’s
disease
87 Had early transfer to phase 2
47 Transferred before 22 wk
40 Transferred before 40 wk
211 Entered phase 2 215 Entered phase 2
4 Were withdrawn early
2 Withdrew consent
1 Moved abroad
1 Was lost to follow-up
48 Needed additional anti-
parkinson medication
4 Were withdrawn early
2 Died
1 Had an adverse event
1 Was lost to follow-up
1 Did not have UPDRS 
at 80 wk
62 Needed additional anti-
parkinson medication
207 Completed the trial 210 Completed the trial
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CI, −1.8 to 3.0; P = 0.60). The change in the UPDRS 
score from baseline to week 40 was −3.1±10.2 in 
the early-start group and 2.0±12.3 in the delayed-
start group (difference, −5.1 points; 95% CI, −7.2 
to −2.9), favoring the early-start group and re-
flecting the effect of levodopa on symptoms of 
the disease. The estimates of the rate of progres-
sion of symptoms (the mean change per week in 
the total UPDRS score) between weeks 4 and 40 
(phase 1) showed no significant difference be-
tween the early-start group (0.04±0.23 points 
per week) and the delayed-start group (0.06±0.34 
points per week) (estimated difference, −0.02 
points; 95% CI, −0.07 to 0.03). The estimates of 
the rate of change between weeks 44 and 80 
(phase 2) were 0.10±0.25 points per week in the 
early-start group as compared with 0.03±0.28 
points per week in the delayed-start group (esti-
mated difference, 0.07 points; 90% CI, 0.03 to 
0.10), which did not meet the criterion for non-
inferiority of early receipt of levodopa to delayed 
receipt. The results of the per-protocol analyses 
showed a pattern that was similar to that of the 
intention-to-treat analyses (Tables S3 and S4 in 
the Supplementary Appendix). At 80 weeks, the 
point estimates and confidence intervals sug-
gested no significant differences between the 
two groups in ALDS, MMSE, BDI-II, and PDQ-39 
scores (Table 2). Figure 2 shows the UPDRS and 
PDQ-39 scores of both groups over the course of 
the trial.
During the first 40 weeks of the trial, the 
incidence of nausea was higher in the early-start 
group than in the delayed start-group (23.0% vs. 
14.3%, P = 0.02) (Table 3). At 80 weeks, the per-
centage of patients with motor complications, 
including dyskinesias and fluctuations in motor 
response, did not differ significantly between 
the two groups (Table S5 in the Supplementary 
Appendix). The results of the other secondary 
outcomes are shown in the Supplementary Ap-
pendix.
Discussion
This randomized trial showed an effect of le-
vodopa on symptoms of Parkinson’s disease in 
the first 40 weeks of the trial (the placebo-con-
trolled phase of the trial) but no significant dif-
ference in the UPDRS score at week 80 (with all 
patients receiving active treatment from week 40 
on), which indicates that the severity of parkin-
sonian symptoms at the end of the trial did not 
differ significantly between patients who received 
Characteristic
Early-Start Group 
(N = 222)
Delayed-Start Group 
(N = 223)
Age — yr 64.8±8.7 65.5±8.8
Age ≥65 yr — no. (%) 129 (58.1) 129 (57.8)
Male sex — no. (%) 157 (70.7) 154 (69.1)
Recruited from academic 
 hospital — no. (%)
62 (27.9) 67 (30.0)
Duration of symptoms <0.5 yr 
— no. (%)
22 (9.9) 26 (11.7)
First symptom — no. (%)†
Tremor 131 (59.0) 130 (58.3)
Bradykinesia 85 (38.3) 76 (34.1)
Rigidity 75 (33.8) 75 (33.6)
Pain 20 (9.0) 21 (9.4)
UPDRS score‡
Total 28.1±11.4 29.3±12.1
Part I 2.4±1.4 2.3±1.2
Part II 7.3±3.6 7.4±3.7
Part III 18.4±8.7 19.5±9.4
Median ALDS score (IQR)§ 89.5 (89.0–89.5) 89.5 (89.0–89.5)
Median MMSE score (IQR)¶ 29.0 (28.0–30.0) 29.0 (28.0–30.0)
Median BDI-II score (IQR)‖ 7.0 (3.0–10.0) 6.0 (4.0–10.0)
Median PDQ-39 score (IQR)** 10.3 (5.8–16.7) 9.0 (5.1–15.4)
*  Plus–minus values are means ±SD. Baseline variables were compared be-
tween the two groups with the use of a two-group t-test, Mann–Whitney 
tests, and chi-square tests; P values ranged between 0.19 and 0.96. IQR 
 denotes interquartile range.
†  Patients could have had more than one first symptom.
‡  Scores on the Unified Parkinson’s Disease Rating Scale (UPDRS) range from 
0 to 176, with higher scores indicating more severe disease; the scale includes 
subscales of mental function (Part I), activities of daily living (Part II), and 
motor function (Part III).
§  Disability was assessed with the use of the Academic Medical Center Linear 
Disability Score (ALDS), which ranges from 0 to 100, with lower scores indi-
cate greater disability.
¶  Cognitive impairment was assessed with the use of the Mini–Mental State 
Examination (MMSE); scores range from 0 to 30, with lower scores indicat-
ing greater cognitive impairment.
‖  Depression was assessed with the use of the Beck Depression Inventory II 
(BDI-II); scores range from 0 to 63, with higher scores indicating more se-
vere depressive symptoms.
**  Disease-related quality of life was assessed with the use of the Parkinson’s 
Disease Questionnaire-39 (PDQ-39); scores range from 0 to 100, with higher 
scores indicating a lower disease-related quality of life.
Table 1. Demographic and Baseline Clinical Characteristics.*
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early initiation of the drug and those who re-
ceived delayed initiation. These findings imply that 
levodopa had no disease-modifying effect on 
Parkinson’s disease over the period of the trial. 
The prespecified analysis of the rate of progres-
sion of symptoms in the second part of the trial, 
which did not show the noninferiority of early 
initiation to delayed initiation, supports this con-
clusion. During the first 40 weeks of the trial, 
nausea was more common among the patients 
who were receiving levodopa than among those 
who were receiving placebo, but the incidence of 
the other adverse events, particularly dyskinesias 
and levodopa-related motor fluctuations, did not 
differ significantly between the two groups.
One interpretation of the outcome of the non-
inferiority analysis during phase 2 of the trial, 
during which both groups were exposed to levo-
dopa and during which the rate of change in the 
UPDRS score was faster in the early-start group 
than in the delayed-start group, is that disease 
progression was more rapid in the early-start 
group. However, the lack of a between-group dif-
ference at week 80 makes it more likely that the 
rate of progression differed because the effect of 
the drug on symptoms of the disease had not yet 
fully accrued in the delayed-start group at week 
44. The slope of UPDRS progression was similar 
in the two groups from week 56 onward (Fig. 2), 
which also supports the latter hypothesis.
Outcome
Early-Start Group 
(N = 207)
Delayed-Start Group 
(N = 210)
Difference between 
Mean Scores 
(95% CI) P Value
Primary outcome: change from baseline to week 80 
in UPDRS score
Baseline 28.0±11.2 29.0±11.8
Week 80 27.0±14.8 27.0±14.3
Difference −1.0±13.1 −2.0±13.0 1.0 (−1.5 to 3.5) 0.44†
Secondary outcome measures‡
Progression of symptoms, as evaluated by an 
 increase in UPDRS score per week
Between wk 4 and wk 40 0.04±0.23 0.06±0.34 −0.02 (−0.07 to 0.03)§
Between wk 44 and wk 80 0.10±0.25 0.03±0.28 0.07 (0.03 to 0.10)¶
Median disability score at 80 wk, as assessed with 
the ALDS (IQR)
89.5 (88.7 to 89.5) 89.5 (88.7 to 89.5) 0.10 (−1.21 to 1.41)‖
Median global cognitive functioning score at 80 wk, 
as assessed with the MMSE (IQR)
29.0 (28.0 to 30.0) 29.0 (28.0 to 30.0) 0.12 (−0.21 to 0.45)‖
Median depression score at 80 wk, as assessed 
with the BDI-II (IQR)
6.0 (3.0 to 10.0) 6.0 (3.0 to 10.0) 0.18 (−0.78 to 1.10)‖
Median disease-related quality of life at 80 wk,  
as assessed with the PDQ-39 (IQR)
7.7 (3.2 to 14.7) 8.3 (3.8 to 14.7) −0.39 (−2.09 to 1.27)‖
*  Plus–minus values are means ±SD.
†  The P value was calculated with the use of a two-group t-test.
‡  Because of the lack of a plan for adjustment for multiplicity, the secondary outcomes are presented as point estimates with unadjusted 95% 
confidence intervals and cannot be used for clinical inferences.
§  The 95% confidence intervals are based on a linear mixed model that included trial group, time (4, 22, and 40 weeks), and an interaction 
between these two variables. Dependency of repeated measures was taken into account by including a random intercept for each patient, 
and maximum likelihood was used as the estimation method.
¶  The prespecified noninferiority margin was 0.055 points on the UPDRS. Because of the use of noninferiority testing, a two-sided 90% confi-
dence interval is reported (95% one-sided confidence interval). The confidence interval is based on a linear mixed model that included trial 
group, time (44, 56, 68, and 80 weeks), and an interaction between these two variables. Dependency of repeated measures was taken into 
account by including a random intercept for each patient, and maximum likelihood was used as the estimation method.
‖  Values were calculated with the use of the bootstrap method (information on bootstrapping specifications can be found in the Supplementary 
Appendix).
Table 2. Primary and Secondary Outcomes.*
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The dose of levodopa (100 mg three times 
per day) in combination with carbidopa (25 mg 
three times per day) that was used in the trial 
was chosen as a compromise between higher 
doses, which are associated with a greater risk 
of side effects, and lower, less effective doses. In 
the ELLDOPA trial, levodopa at a dose of 100 mg 
three times per day in combination with carbi-
dopa at a dose of 25 mg three times per day was 
in the middle of the range of three doses tested.4 
The choice of 40 weeks as the duration of each 
phase was the result of two considerations. First, 
phase 1 had to be long enough to allow any 
disease-modifying effect of the active drug to 
become apparent later in the trial. In previous 
placebo-controlled, delayed-start trials that eval-
uated early Parkinson’s disease, the duration of 
phase 1 was 26 to 40 weeks.14-16 Second, the 
duration of phase 2 had to be long enough for 
treatment to fully exert an effect on symptoms 
in the delayed-start group but could not be so 
long that most patients would be expected to 
need additional treatment for symptoms.
During phase 1 of the trial (the first 40 
weeks), 39% of the patients in the delayed-start 
group proceeded to receive the phase 2 trial 
medication (levodopa), and 11% in the early-
start group proceeded to open-label treatment 
with the same dose of levodopa. This resulted 
in a comparatively shorter mean time that 
treatment with levodopa could exert a possible 
disease-modifying effect in the early-start group 
than in the delayed-start group. However, the 
results of the per-protocol analyses, which took 
the switch to levodopa into account, were 
similar to the results of the intention-to-treat 
analysis.
In patients with early Parkinson’s disease, the 
clinical diagnosis may be incorrect in up to 15% 
of patients.4,17 Confirmatory neuroimaging of 
the dopamine transporter was not a prerequisite 
for participation in the trial. However, 22% of 
the entire cohort had undergone imaging of the 
dopamine transporter, which confirmed degen-
eration of substantia nigra neurons, before evalu-
ation for eligibility.
We conclude that treatment with levodopa at 
a dose of 100 mg three times per day in com-
bination with carbidopa at a dose of 25 mg 
three times per day had no disease-modifying 
effect, either beneficial or detrimental, on early 
Parkinson’s disease among patients who were 
evaluated over the course of 80 weeks. Whether 
higher doses of the drug, longer periods of 
administration, or initiation of the drug at later 
stages of the disease could alter the course of 
Parkinson’s disease warrants evaluation in fu-
ture trials.
Figure 2. Unified Parkinson’s Disease Rating Scale and Parkinson’s Disease 
Questionnaire-39 Scores during the Trial.
The analyses were based on the intention-to-treat population. Mean Uni-
fied Parkinson’s Disease Rating Scale (UPDRS) total scores (Panel A) and 
Parkinson’s Disease Questionnaire-39 (PDQ-39) scores (Panel B) for each 
trial group are shown. UPDRS scores range from 0 to 176, with higher 
scores indicating more severe disease; the scale includes subscales of 
mental function, activities of daily living, and motor function. PDQ-39 
scores range from 0 to 100, with higher scores indicating a lower disease- 
related quality of life. I bars denote 95% confidence intervals.
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Event Phase 1 Phase 2
Early-Start Group, 
Levodopa 
(N = 222)
Delayed-Start Group, 
Placebo 
(N = 223)
Early-Start Group, 
Levodopa 
(N = 211)
Delayed-Start Group, 
Levodopa 
(N = 215)
Adverse event — no. (%)†
Nausea 51 (23.0) 32 (14.3) 26 (12.3) 40 (18.6)
Constipation 8 (3.6) 8 (3.6) 5 (2.4) 11 (5.1)
Light-headedness when standing 17 (7.7) 21 (9.4) 12 (5.7) 14 (6.5)
Daytime sleepiness 1 (0.5) 3 (1.3) 4 (1.9) 1 (0.5)
Impulse control disorder 1 (0.5) 0 2 (0.9) 0
Hallucinations 10 (4.5) 14 (6.3) 11 (5.2) 12 (5.6)
Dizziness 33 (14.9) 32 (14.3) 18 (8.5) 22 (10.2)
Tiredness 10 (4.5) 17 (7.6) 10 (4.7) 12 (5.6)
Worsening of parkinsonism 31 (14.0) 41 (18.4) 43 (20.4) 41 (19.1)
Depression 4 (1.8) 3 (1.3) 7 (3.3) 5 (2.3)
Pain 9 (4.1) 2 (0.9) 7 (3.3) 5 (2.3)
Falls 7 (3.2) 6 (2.7) 7 (3.3) 8 (3.7)
Greasy skin 23 (10.4) 23 (10.3) 15 (7.1) 12 (5.6)
Headache 3 (1.4) 9 (4.0) 4 (1.9) 8 (3.7)
Upper respiratory tract infection 3 (1.4) 8 (3.6) 8 (3.8) 5 (2.3)
Serious adverse event — no. of events‡
Nausea 1 0 1 0
Orthostatic hypotension 0 1 1 0
Hallucinations 0 0 0 1
Falls 0 0 0 2
Falls with bone fracture 0 2 1 1
Cardiac arrhythmia 2 0 1 2
Myocardial infarction 1 1 1 1
Transient ischemic attack or stroke 1 3 1 3
Cancer other than melanoma 1 0 1 2
Melanoma 0 0 0 1
Surgery not related to Parkinson’s 
disease (e.g., knee or cataract 
surgery)
5 8 6 4
Infection (e.g., urinary tract infection 
or pneumonia)
0 1 0 1
Pulmonary embolism 0 1 0 1
*  For patients who proceeded to receive the trial regimen of phase 2 before week 40, adverse events that occurred before the switch were in-
cluded in phase 1 for the analysis; adverse events that occurred after the switch were included in phase 2. Variables were compared between 
the two groups for the same phase with the use of chi-square tests; P values ranged between 0.02 and 0.99. The only significant difference 
observed between the early-start group (levodopa) and the delayed-start group (placebo) was the incidence of nausea during phase 1 (P = 0.02).
†  Included are adverse events that occurred in more than 3% of the patients in either group in either phase of the trial and adverse events of 
special interest (e.g., daytime sleepiness or impulse control disorder).
‡  An adverse event was categorized as a serious adverse event if it resulted in a visit to the emergency department, hospitalization, or persis-
tent disability or death.
Table 3. Adverse Events, According to Phase and Trial Group.*
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